Related Experiment Videos
Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies
David A Braun1, Catherine J Wu
1From the *Department of Medical Oncology, Dana-Farber Cancer Institute; †Department of Medicine, Brigham and Women's Hospital, Harvard Medical School; and ‡Massachusetts General Hospital Cancer Center, Boston; and §Broad Institute of MIT and Harvard, Cambridge, MA.
Cancer Journal (Sudbury, Mass.)
|April 15, 2017
Summary
Immuno-oncology is transforming hematologic malignancy treatment. This review explores novel tumor antigens and immunotherapies, including personalized cancer vaccines and adoptive cell therapy, for improved outcomes.
Area of Science:
- Oncology
- Immunology
- Hematology
Background:
- Immune-based therapies, including stem cell transplantation, have historically been crucial for treating blood cancers.
- The development of targeted immunotherapies is expanding treatment options for hematologic malignancies.
Purpose of the Study:
- To review antigen discovery and known/novel tumor antigens in hematologic malignancies.
- To explore established and investigational immunotherapies for blood cancers.
- To focus on personalized treatment modalities like cancer vaccines and adoptive cell therapy.
Main Methods:
- Literature review of antigen discovery approaches.
- Analysis of current and emerging immunotherapies for hematologic malignancies.
- Discussion of personalized treatment strategies.
Main Results:
- Identification of key tumor antigens and their role in hematologic malignancies.
- Overview of various immunotherapeutic strategies, including adoptive cell therapy and cancer vaccines.
- Highlighting the potential for personalized treatment approaches.
Conclusions:
- Immunotherapy represents a rapidly evolving and promising frontier in hematologic malignancy treatment.
- Further research is essential to develop effective, targeted immune therapies that optimize antitumor activity and minimize toxicity.